Fortress Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fortress Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-746	Closed	-$67K	–	81
2014 Q4	$67K	Buy	+746	New	+$62K	﹤0.01%	162
2014 Q3	–	Sell	-3,322	Closed	-$207K	–	175
2014 Q2	$207K	Hold	3,322	–	–	﹤0.01%	134
2014 Q1	$227K	Sell	3,322 -60	-2%	-$4.42K	﹤0.01%	122
2013 Q4	$238K	Buy	3,382 +1,264	+60%	+$85.8K	﹤0.01%	110
2013 Q3	$153K	Buy	2,118 +355	+20%	+$23.6K	﹤0.01%	130
2013 Q2	$98K	Buy	+1,763	New	+$110K	﹤0.01%	123

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fortress Investment Group's BMRN Position: Q1 2015 in Review

Fortress Investment Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2015, closing a stake of 746 shares — an estimated $67K sold.

Fortress Investment Group first reported a position in BMRN in Q2 2013 and held it in 6 quarters. The position peaked at $238K in Q4 2013. 377 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

Fortress Investment Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Fortress Investment Group sold 746 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $67K.
Fortress Investment Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Fortress Investment Group's BioMarin Pharmaceuticals position peaked at $238K in Q4 2013.
377 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on Fortress Investment Group's 13F filing for Q1 2015, filed 15 May 2015.